New research from Tel Aviv University in the battle against Alzheimer’s

Alzheimer

There are still many unknowns surrounding the origins of Alzheimer’s disease. What we do know for certain is that Alzheimer’s causes devastating effects in its victims, including memory loss and cognitive degeneration. 

For this reason, even small steps in the fight against the “memory disease” are always big news, especially when it comes to those holding out hope for the future. Such is the case with a recent study from Tel Aviv University, which may prove to be an important advance in protecting Alzheimer’s sufferers from the damage wrought by the disease. NAP, a protective peptide The key to the study, published in the Journal of Alzheimer’s Disease, is the identification of “shields” which potentially defend the brain cells of Alzheimer’s patients against the disease’s effects. Research focused on the NAP peptide (also known Read more

Mobile apps for our health

Some people think of mobile apps as purely for entertainment and, with their risks of prolonged screen exposure and eye strain from peering at small fonts, perhaps even harmful to our health. However, smartphones and similar devices, already very much a part of our lives, can also provide “healthy” solutions within arm’s reach.

Instant messaging, driver navigation and social networking give us real time connections to the things that matter…yet these are just a small part of the potential that smartphones have to make meaningful contributions to our health and quality of life. We can’t turn a blind eye to the world’s vision problems According to the World Health Organisation, over 280 million people around the planet suffer from some type of vision problem. In the majority of cases, the key to fighting these conditions lies in obtaining the right diagnosis as early as possible, improving the chances for successful treatment. Peek Vision …what’s your Read more

New treatments to counteract lymphoma tumour resistance

With 66,000 new cases of non-Hodgkin lymphoma diagnosed per year in the United States alone, lymphoma, a type of cancer that originates in the lymphatic system, poses a considerable challenge for the medical and scientific community. Yet advances continue to be made in the research of new treatments to alleviate the effects of this disease.

One of the latest lymphoma medications to be commercialised is ibrutinib. A drug belonging to the class of kinase inhibitors, ibrutinib blocks the action of the abnormal protein responsible for sending signals that tell tumour cells to multiply and is therefore able to stop cancer from spreading. Tumour cell resistance to ibrutinib To date, ibrutinib’s results have been cause for hope, reducing or completely stopping tumour growth in 68% of patients receiving treatment. However, a recent study on ibrutinib conducted by Weill Cornell Medical College in New York, found that, in a large number of patients, lymphoma cells become resistant to the drug. Read more